Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IDH2 Mutation Clear all
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
View directory record Official record
Conditions
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
Interventions
CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

NCT05282459
View directory record Official record
Conditions
Leukemia, Leukemia, Myeloid, Monocytic Leukemia
Interventions
Enasidenib mesylat dose escalation
Drug
Lead sponsor
Tian Yi Zhang
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional

Chronic CED of TPT for Recurrent Malignant Glioma

NCT06666712
View directory record Official record
Conditions
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
Interventions
Topotecan
Drug
Lead sponsor
Jeffrey N. Bruce
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738, Venetoclax, Azacitidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

NCT02677922
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AG-120, Azacitidine, AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

NCT02481154
View directory record Official record
Conditions
Glioma
Interventions
AG881
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901
View directory record Official record
Conditions
Grade 2 Glioma, Residual Glioma, Recurrent Glioma
Interventions
Vorasidenib, Matching Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

NCT06240754
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
Interventions
Enasidenib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

NCT02492737
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
Interventions
AG881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

NCT03728335
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Enasidenib Mesylate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Duarte, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
141
States / cities
Berkeley, California • Irvine, California • Orange, California + 117 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Withdrawn Phase 1 Interventional

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

NCT04955938
View directory record Official record
Conditions
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
Interventions
Ivosidenib, Enasidenib, Fedratinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 22, 2026, 4:55 PM EDT
Withdrawn Phase 2 Interventional

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

NCT03881735
View directory record Official record
Conditions
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Enasidenib, Hematopoietic Cell Transplantation
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Buffalo, New York • East Hills, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

NCT04203316
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Enasidenib, Enasidenib Mesylate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
24 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 1 Interventional

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708
View directory record Official record
Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT05441514
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cobimetinib, Enasidenib Mesylate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

NCT05756777
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Gilteritinib, Ivosidenib, Enasidenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

NCT04281498
View directory record Official record
Conditions
Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
Interventions
Ruxolitinib, Enasidenib
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

NCT03683433
View directory record Official record
Conditions
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Enasidenib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional

CPX-351 Plus Enasidenib for Relapsed AML

NCT03825796
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 4:55 PM EDT
Active, not recruiting Early Phase 1 Interventional

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700
View directory record Official record
Conditions
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
Interventions
Niraparib, Resection/Treatment with Niraparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

NCT01915498
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
19
States / cities
Duarte, California • Stanford, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742
View directory record Official record
Conditions
IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 22, 2026, 4:55 PM EDT